Circulating annexin A2 as a biomarker in gastric cancer patients: Correlation with clinical variables


Tas F. , Yasasever C. T. , Karabulut S., Tastekin D. , Duranyildiz D.

Biomedicine and Pharmacotherapy, cilt.69, ss.237-241, 2015 (SCI Expanded İndekslerine Giren Dergi) identifier identifier identifier

  • Cilt numarası: 69
  • Basım Tarihi: 2015
  • Doi Numarası: 10.1016/j.biopha.2014.12.005
  • Dergi Adı: Biomedicine and Pharmacotherapy
  • Sayfa Sayıları: ss.237-241

Özet

© 2014 Elsevier Masson SAS.Annexin A2 (ANXA2) plays an important role in the pathogenesis of multiple malignancies and its expression strongly also affects the outcomes of cancer patients. The objective of this study was to determine the clinical significance of the serum levels of ANXA2 in patients with gastric cancer. A total of 63 patients with a pathologically confirmed diagnosis of gastric cancer were enrolled into this study. Serum ANXA2 concentrations were determined by the solid-phase sandwich ELISA method. Age- and sex-matched 30 healthy controls were included in the analysis. The median age at diagnosis was 62. years, range 28 to 82. years. The baseline serum ANXA2 levels of the gastric cancer patients were a significantly higher than those in the control group (P< 0.001). The known clinical variables including age of patient, gender, site of lesion, histology, histological grade, stage of disease, and serum levels of LDH, carcinoembryonic antigen (CEA), and carbohydrate antigen (CA) 19.9 were not found to be correlated with serum ANXA2 concentrations (P> 0.05). However, the chemotherapy-unresponsive patients had higher serum ANXA2 levels compared with chemotherapy-responsive ones (P= 0.04). Conversely, serum ANXA2 concentration was found no prognostic role on survival (P= 0.53). In conclusion, serum levels of ANXA2 may have a good diagnostic and predictive marker for response to chemotherapy in patients with gastric cancer and have not associated with prognosis.